Ocular Therapeutix Inc. (0OT)

Overview

Ocular Therapeutix, Inc. is a progressive biopharmaceutical entity with a dedicated focus on crafting, developing, and commercializing innovative therapies for eye diseases and conditions. Leveraging its proprietary bioresorbable hydrogel-based formulation technology, the company is at the forefront of addressing significant unmet medical needs in ophthalmology in the United States. Its collaboration with industry leaders such as Regeneron Pharmaceuticals, Inc. and AffaMed Therapeutics Limited underscores its commitment to advancing ophthalmic care through sustained-release hydrogel solutions and enhanced drug delivery systems. Founded in 2006, Ocular Therapeutix has established its headquarters in Bedford, Massachusetts, marking a significant presence in the biopharmaceutical sector with its groundbreaking approach to eye care.

Products and Services

• DEXTENZA

  A cornerstone of Ocular Therapeutix's market offerings, DEXTENZA is an FDA-approved dexamethasone ophthalmic insert designed for the treatment of post-surgical ocular inflammation and pain following ophthalmic surgery. Additionally, it is indicated for the treatment of allergic conjunctivitis. DEXTENZA represents a leap forward in ocular pain management and inflammation control, providing sustained relief through a bioresorbable hydrogel-based insert.

• AXPAXLI

  Currently in phase 3 trials, AXPAXLI is an axitinib intravitreal implant developed for the treatment of wet age-related macular degeneration (AMD) and other retinal diseases. AXPAXLI exemplifies Ocular Therapeutix's commitment to addressing the challenges of AMD, a leading cause of vision loss, through innovative, sustained-release drug delivery technologies.

• PAXTRAVA

  PAXTRAVA, a travoprost intracameral implant, is undergoing phase 2 clinical trials. It is aimed at treating open-angle glaucoma or ocular hypertension by offering a novel, sustained-release solution to reduce intraocular pressure, a key factor in the progression of glaucoma.

• OTX-CSI

  Having completed phase 2 clinical trials, OTX-CSI is a cyclosporine intracanalicular insert designed for the treatment of dry eye disease. OTX-CSI represents an innovative approach to managing dry eye symptoms by providing sustained cyclosporine delivery directly to the ocular surface.

• OTX-DED

  In phase 2 clinical trials, OTX-DED is a dexamethasone intracanalicular insert developed for the short-term treatment of the signs and symptoms of dry eye disease. This offering highlights Ocular Therapeutix's dedication to improving patient outcomes in dry eye management through its proprietary hydrogel technology.

• Gene Delivery & Protein Biofactory

  The company is also engaged in developing gene delivery solutions for inherited retinal degenerations and leveraging its platform as a protein biofactory for various indications. These frontier areas of research have the potential to offer transformative treatments for complex ophthalmic diseases.